evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

63 questions · 69 findings · 8 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 20 · 29%GRADE not reported 1 · 1.4%Very low 11 · 15.9%Low 19 · 27.5%Moderate 14 · 20.3%High 4 · 5.8%

IVIg vs PE

Number improved by 1 or more disability grades after 4 weeks · patients with Guillain‐Barré syndrome

IVIg showed no clear difference in number improved by 1 or more disability grades after 4 weeks compared with PE (moderate certainty).

1 finding from 1 review

IVIg vs PE

Dead or disabled after 12 months (48 weeks) · patients with Guillain‐Barré syndrome

IVIg showed no clear difference in dead or disabled after 12 months (48 weeks) compared with PE (low certainty).

1 finding from 1 review

IVIg vs PE

Relapse or treatment‐related fluctuation · patients with Guillain‐Barré syndrome

IVIg showed no clear difference in relapse or treatment‐related fluctuation compared with PE (low certainty).

1 finding from 1 review

IVIg vs PE

Patients in whom treatment was discontinued · patients with Guillain‐Barré syndrome

IVIg leads to lower participants in whom treatment was discontinued compared with PE (high certainty).

1 finding from 1 review

IVIg vs PE

Number of patients with adverse events attributed to treatment · patients with Guillain‐Barré syndrome

IVIg showed no clear difference in number of participants with adverse events attributed to treatment compared with PE (moderate certainty).

1 finding from 1 review

IVIg vs placebo or no intervention

All‐cause mortality, neonates, standard polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock

Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in all‐cause mortality, neonates, standard polyclonal IVIG compared with placebo or no intervention (moderate certainty).

2 findings from 1 review

IVIg vs placebo or no intervention

All‐cause mortality, neonates, IgM‐enriched polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock

Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in all‐cause mortality, neonates, IgM‐enriched polyclonal IVIG compared with placebo or no intervention (low certainty).

1 finding from 1 review

IVIg vs placebo or no intervention

28‐Day all cause mortality (adult studies) · adult patients with sepsis, severe sepsis and septic shock

Polyclonal intravenous immunoglobulin (IVIG) probably leads to lower all‐cause mortality, adults, standard polyclonal IVIG compared with placebo or no intervention (moderate certainty).

5 findings from 1 review
Show 2 more findings

IVIg vs no IVIG

Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

It is very uncertain whether intravenous immunoglobulin (IVIG) changes SJS/TEN‐specific mortality (time to compared with no IVIG (very low certainty).

1 finding from 1 review